EHR study links semaglutide and tirzepatide to fewer anxiety, depression diagnoses

The wire

1. 01A US electronic health record study found adults with obesity starting semaglutide or tirzepatide had lower recorded hazards of anxiety and depression than matched naltrexone-bupropion users.
2. 02Clinicians weighing psychiatric history when choosing obesity pharmacotherapy now have comparative signal, though the two incretins diverged in the non-diabetic subgroup.
3. 03Recorded diagnoses in claims-style data are not structured assessments, and residual confounding by indication remains; authors call for cautious monitoring rather than changed practice.

From the source

Study links semaglutide and tirzepatide to fewer anxiety and depression diagnoses in obesity care

A US electronic health record study found that adults with obesity who started semaglutide or tirzepatide had lower recorded hazards of anxiety and depression than matched patients using naltrexone-bupropion. However, among adults without type 2 diabetes, tirzepatide was linked to higher recorded hazards of anxiety and insomnia than semaglutide, underscoring the need for cautious monitoring.